Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
ReutersDec 17, 2025 2:38 PM
Dec 17 (Reuters) - Structure Therapeutics Inc GPCR.O:
STRUCTURE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 FOR THE TREATMENT OF OBESITY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
US Q3 GDP Released, Will US Stocks See a "Santa Claus Rally"?【The week ahead】
TradingKey - This week, global financial markets will enter "Christmas mode." Investors should focus on US GDP data, and Bank of Japan Governor Kazuo Ueda will deliver a speech, potentially offering clues on the interest rate trajectory for 2026.TradingKey
14 hours ago
Rocket Lab Stock Analysis: Why Is Rocket Lab Stock Price Soaring? Is Now a Good Time To Buy?
TradingKey - Even though Rocket Lab's stock price has seen substantial gains from its previous levels, we believe that Rocket Lab still offers speculative value.TradingKey
23 hours ago
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Musk’s Next Ambition: Building a Space-Based AI Data Center
TradingKey - Musk has long resisted the idea of taking SpaceX public. After the Tesla take-private drama and the resulting SEC penalties (which cost him the chairmanship), he’s been wary of public market entanglements. But something’s changed—and fast.TradingKey
Thu, Dec 18
Tradingkey
